Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01753193 · ClinicalTrials.gov registry record · Phase 2

An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults

A Phase 2 study of Lupus Erythematosus, Systemic, sponsored by MedImmune.

Completed
Registry status
Phase 2
Development phase
218
Enrollment target
20
Study locations

NCT01753193 is a Phase 2 study of Lupus Erythematosus, Systemic that has completed, run by MedImmune. The registered enrollment target is 218 participants, above the 196-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01753193, a Phase 2 study of Lupus Erythematosus, Systemic, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 2
Development phase
218 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the long-term safety of anifrolumab (MEDI-546) in adults with moderate to severe active systemic lupus erythematosus (SLE).

Conditions Studied

Lupus Erythematosus, Systemic

Interventions

  • BIOLOGICAL Anifrolumab

Study Locations (20)

California

  • Research Site - La Palma
  • Research Site - Long Beach
  • Research Site - Los Angeles
  • Research Site - Palm Desert
  • Research Site - Upland

Florida

  • Research Site - Ocala
  • Research Site - Orlando
  • Research Site - Tampa

Georgia

  • Research Site - Atlanta
  • Research Site - Stockbridge

North Carolina

  • Research Site - Charlotte
  • Research Site - Raleigh

Alabama

  • Research Site - Birmingham

Illinois

  • Research Site - Chicago

Indiana

  • Research Site - Indianapolis

New Mexico

  • Research Site - Las Cruces

Trial Details

FieldValue
Enrollment Target 218 participants
Start Date 2013-03-28
Est. Completion 2018-07-18
Phase Phase 2

Sponsor

MedImmune

210 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01753193

The ClinicalTrials.gov registry entry for NCT01753193 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (11% higher). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 1 intervention - of which Anifrolumab is the first listed.

NCT01753193 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT01753193 about?

NCT01753193 is a clinical study titled "An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults". The purpose of this study is to evaluate the long-term safety of anifrolumab (MEDI-546) in adults with moderate to severe active systemic lupus erythematosus (SLE).

What is the current status of trial NCT01753193?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 218 participants. The study started on 2013-03-28. Estimated completion is 2018-07-18.

What conditions does trial NCT01753193 study?

This clinical trial studies the following conditions: Lupus Erythematosus, Systemic.

What interventions are being tested in trial NCT01753193?

The interventions under investigation include: Anifrolumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT01753193?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01753193 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lupus Erythematosus, Systemic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lupus Erythematosus, Systemic

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.